Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Rises By 7,658.5%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 473,657 shares, an increase of 7,658.5% from the June 30th total of 6,105 shares. Approximately 7.8% of the shares of the company are short sold. Based on an average daily volume of 2,079,462 shares, the short-interest ratio is currently 0.2 days.

Matinas Biopharma Price Performance

Shares of Matinas Biopharma stock opened at $0.24 on Friday. The company’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $0.61. The firm has a market capitalization of $1.55 million, a PE ratio of -0.12 and a beta of 1.71. Matinas Biopharma has a 52-week low of $0.23 and a 52-week high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent filing with the SEC. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.